Erica Rogers - Silk Road President CEO, Director

SILKDelisted Stock  USD 27.49  0.00  0.00%   

CEO

Ms. Erica J. Rogers is the President, Chief Executive Officer, Director at Silk Road Medical Inc. Prior to Silk Road Medical, Erica was the COO of Medicines360, a nonprofit pharmaceutical company developing drugs and devices for women. Erica was the founder and CEO of Allux Medical, as well as the cofounder of Visiogen, which was acquired by Abbott Medical Optics in 2009. Erica spent over 12 years at Boston Scientific, in sales and marketing positions. She began her career in pharmaceutical sales after receiving a B.S. in zoology from San Diego State University. Erica holds five issued and 15 pending US patents in medical devices and nanotechnology.
Age 61
Phone408 720 9002
Webhttps://silkroadmed.com

Silk Road Management Efficiency

The company has return on total asset (ROA) of (0.1411) % which means that it has lost $0.1411 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3645) %, meaning that it created substantial loss on money invested by shareholders. Silk Road's management efficiency ratios could be used to measure how well Silk Road manages its routine affairs as well as how well it operates its assets and liabilities.
Silk Road Medical currently holds 84.63 M in liabilities with Debt to Equity (D/E) ratio of 1.37, which is about average as compared to similar companies. Silk Road Medical has a current ratio of 6.78, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Silk Road's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 10 records

CEO Age

Damien McDonaldLivaNova PLC
59
Ronald MDRxsight
61
Mark ThrodahlOrthopediatrics Corp
73
Steven WilliamsonPulmonx Corp
51
Joel BeckerNeuropace
56
Massimo CalafioreOrthofix Medical
52
Glendon FrenchPulmonx Corp
62
Karen ZaderejAxogen Inc
62
Albert DaCostaParagon 28
51
Vladimir MakatsariaLivaNova PLC
51
Silk Road Medical, Inc. operates as a medical device company in the United States. The company was incorporated in 2007 and is headquartered in Sunnyvale, California. Silk Road operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 352 people. Silk Road Medical (SILK) is traded on NASDAQ Exchange in USA and employs 474 people.

Management Performance

Silk Road Medical Leadership Team

Elected by the shareholders, the Silk Road's board of directors comprises two types of representatives: Silk Road inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Silk. The board's role is to monitor Silk Road's management team and ensure that shareholders' interests are well served. Silk Road's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Silk Road's outside directors are responsible for providing unbiased perspectives on the board's policies.
Erica Rogers, President CEO, Director
Sumaira Macdonald, Chief Medical Officer
Mhairi Jones, VP Accounting
Sumaira MD, Executive Director
Kevin Ballinger, Chief Sec
Tammy Leitsinger, Compliance Affairs
Kevin Klemz, Chief EVP
Alison Highlander, Vice Resources
Jorge OHara, Business Marketing
Charles McKhann, Chief Officer
Richard Ruedy, Executive Vice President - Regulatory Affairs, Clinical Affairs & Quality Assurance
Lucas Buchanan, CFO COO
Lynn Lewis, Investors Officer
Andrew Davis, Chief Officer
Matthew McCarthy, Vice Marketing

Silk Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Silk Road a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in Silk Stock

If you are still planning to invest in Silk Road Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Silk Road's history and understand the potential risks before investing.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Global Correlations
Find global opportunities by holding instruments from different markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Fundamental Analysis
View fundamental data based on most recent published financial statements